JOHN WATSON MELLORS
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD044107L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15218
Personal information
See more information about JOHN WATSON MELLORS at radaris.comName
Address
Phone
201 Beech St, Pittsburgh, PA 15218
3097 E Brighton St, Furlong, PA 18925
Fairless Hills, PA
201 Beech St, Pittsburgh, PA 15218
731 Gilbert Pl, Collegeville, PA 19426
Professional information
Md At Self-Employed
Position:
MD at Self-employed, Professor of Medicine at University of Pittsburgh
Location:
Greater Pittsburgh Area
Industry:
Research
Work:
Self-employed
-
MD
University of Pittsburgh
since 1991
-
Professor of Medicine
Dr. John W Mellors, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
University Pttsbrgh Infcts Diss
3550 Terrace St SUITE 818, Pittsburgh 15213
(412) 624-8512 (Phone)
3550 Terrace St SUITE 818, Pittsburgh 15213
(412) 624-8512 (Phone)
Certifications:
Infectious Disease, 1986, Internal Medicine, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Dartmouth College
Graduated: 1978
Yale New Haven Hospital
Dartmouth College
Graduated: 1978
Yale New Haven Hospital
John W Mellors, Pittsburgh PA
Specialties:
Internist
Address:
3601 5Th Ave, Pittsburgh, PA 15213
Education:
Dartmouth College, Medical School - Doctor of Medicine
Yale New Haven Psychiatric Hospital - Fellowship - Infectious Disease (Internal Medicine)
Yale New Haven Psychiatric Hospital - Residency - Internal Medicine
Yale New Haven Psychiatric Hospital - Fellowship - Infectious Disease (Internal Medicine)
Yale New Haven Psychiatric Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Infectious Disease (Internal Medicine)
Treatment Of Drug-Resistant Human Immunodeficiency Virus Infection
US Patent:
2003020, Nov 6, 2003
Filed:
Oct 30, 2002
Appl. No.:
10/169432
Inventors:
Karl Hostetler - Del Mar CA, US
John Mellors - Pittsburgh PA, US
John Mellors - Pittsburgh PA, US
International Classification:
A61K031/66
US Classification:
514/114000, 514/125000
Abstract:
The invention provides methods for treating HIV infection in a subject in need thereof comprising lipid analogs of phosphonoformate-containing pharmaceutically active compounds. Lipid analogs contemplated for use in the practice of the present invention comprise phosphonoformates covalently linked (directly or indirectly through a linker molecule) to a substituted or unsubstituted alkylglycerol, alkylpropanediol, alkylethanediol, or related moiety. In particular, the invention provides methods for treating viral infections caused by viruses which have developed resistance to currently available antiviral agents, as well as methods comprising the use of invention compounds in combination with azidodeoxythymidine to minimize the selection of drug-resistant HIV variants during therapy.
Compositions And Methods For Use Of Antiviral Drugs In The Treatment Of Retroviral Diseases Resistant To Nucleoside Reverse Transcriptase Inhibitors
US Patent:
2005011, May 26, 2005
Filed:
Sep 9, 2004
Appl. No.:
10/937683
Inventors:
John Mellors - Pittsburgh PA, US
Eric Oldfield - Champaign IL, US
Zev Tovian - Highland Park IL, US
Julian Chan - Urbana IL, US
Eric Oldfield - Champaign IL, US
Zev Tovian - Highland Park IL, US
Julian Chan - Urbana IL, US
International Classification:
A61K031/7072, A61K031/66
US Classification:
514049000, 514102000
Abstract:
The present invention relates to novel compositions comprising an excision-inhibiting bisphosphonate and a nucleoside reverse transcriptase inhibitor. The present invention also relates to methods for preventing or treating retrovirus-related diseases using a composition comprising a bisphosphonate and a nucleoside reverse transcriptase inhibitor. In a specific embodiment, the invention provides methods for preventing or treating AIDS by administering a bisphosphonate-based compound in combination with 3′-azido-3′-deoxythymidine (AZT) to patients infected with AZT-resistant HIV to improve the effectiveness of AZT therapy.
Azido Purine Nucleosides For Treatment Of Viral Infections
US Patent:
2010027, Nov 4, 2010
Filed:
May 14, 2008
Appl. No.:
12/599951
Inventors:
Raymond F. Schinazi - Atlanta GA, US
John W. Mellors - Pittsburgh PA, US
Nicolas Paul Sluis-Cremer - Pittsburgh PA, US
Frank Amblard - Atlanta GA, US
Steven J. Coats - McDonough GA, US
Junxing Shi - Duluth GA, US
Richard Anthony Whitaker - Loganville GA, US
John W. Mellors - Pittsburgh PA, US
Nicolas Paul Sluis-Cremer - Pittsburgh PA, US
Frank Amblard - Atlanta GA, US
Steven J. Coats - McDonough GA, US
Junxing Shi - Duluth GA, US
Richard Anthony Whitaker - Loganville GA, US
Assignee:
RFS PHARMA, LLC - Tucker GA
EMORY UNIVERSITY - Atlanta GA
UNIVERSITY OF PITTSBURGH - Pittsburgh PA
EMORY UNIVERSITY - Atlanta GA
UNIVERSITY OF PITTSBURGH - Pittsburgh PA
International Classification:
A61K 31/70, C07H 19/16, C07D 473/00, A61K 31/522, A61P 31/18
US Classification:
514 45, 536 2722, 544276, 51426337
Abstract:
The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, HBV, and HCV, in human patients or other animal hosts. The compounds are 3′-azido-2′,3′-dideoxy purine nucleosides or phosphonates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 resistance mutants including HIV-1, HTV-1, HIV-1, HIV-1, HIV-1and inhibitory activity against HIV-1 RT harboring TAMS or insertion mutations including HIV-1, HIV-1, HIV-1, HIV-1, or HIV-1. In one embodiment, the compounds are 3′-azido-ddA, 3′-azido-ddG, or combinations thereof, administered with one or more additional antiviral agents that select for TAM mutations and/or the M 184V mutation, along with a pharmaceutically acceptable carrier.
Hiv-1 Mutations Selected For By Β-2′,3′-Didehydro-2′,3′-Dideoxy-5-Fluorocytidine
US Patent:
7635690, Dec 22, 2009
Filed:
Oct 3, 2006
Appl. No.:
11/542044
Inventors:
Raymond F. Schinazi - Decatur GA, US
Jennifer L. Hammond - Pittsburgh PA, US
John W. Mellors - Pittsburgh PA, US
Dennis C. Liotta - McDonough GA, US
Jennifer L. Hammond - Pittsburgh PA, US
John W. Mellors - Pittsburgh PA, US
Dennis C. Liotta - McDonough GA, US
Assignee:
Emory University - Atlanta GA
International Classification:
A61K 31/70, A01N 43/62, A61K 31/535, A01N 43/90, A61K 31/519, A61K 31/497, A61K 31/44, A61K 31/34
US Classification:
514 45, 514 46, 514 47, 514 48, 514 49, 514 50, 514 51, 514220, 5142305, 5142315, 51425212, 514301, 514473, 5142611
Abstract:
The present invention discloses a method for treating HIV that includes administering β-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using β-D-D4FC as “salvage therapy” to patients which exhibit drug resistance to other anti-HIV agents. β-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.
Hiv-1 Mutations Selected For By Beta-2',3'-Didehydro-2',3'-Dideoxy-5-Fluorocytidine
US Patent:
2004008, Apr 29, 2004
Filed:
Jan 23, 2003
Appl. No.:
10/351170
Inventors:
Raymond Schinazi - Decatur GA, US
Jennifer Hammond - Pittsburgh PA, US
John Mellors - Pittsburgh PA, US
Dennis Liotta - McDonough GA, US
Jennifer Hammond - Pittsburgh PA, US
John Mellors - Pittsburgh PA, US
Dennis Liotta - McDonough GA, US
International Classification:
A61K031/655, A61K031/538, A61K031/522
US Classification:
514/151000, 514/230500, 514/263380, 514/269000, 514/046000
Abstract:
The present invention discloses a method for treating HIV that includes administering -D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using -D-D4FC as “salvage therapy” to patients which exhibit drug resistance to other anti-HIV agents. -D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.
Method Of Detecting Azt Resistance In Hiv
US Patent:
2007019, Aug 23, 2007
Filed:
Jan 30, 2007
Appl. No.:
11/699941
Inventors:
John Mellors - Pittsburgh PA, US
Dianna Koontz - Pittsburgh PA, US
Jessica Brehm - Pittsburgh PA, US
Dianna Koontz - Pittsburgh PA, US
Jessica Brehm - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Pittsburgh PA
International Classification:
C12Q 1/68, C12P 19/34, C12N 5/06, C12N 5/16
US Classification:
435091100, 435345000, 435006000
Abstract:
Described herein is a method of determining the presence of a nucleoside reverse transcriptase inhibitor-resistant Human Immunodeficiency Virus-1 (HIV-1) virus particle in a biological sample, comprising identifying the presence in the sample of a point mutation at codon Q509 of an HIV-1 reverse transcriptase, for example and without limitation Q509L. That point mutation increases resistance to AZT about 3- to 10-fold by itself and about 50-fold in combination with the connection domain mutation A371V.
3'-Azido Purine Nucleotide Prodrugs For Treatment Of Viral Infections
US Patent:
2012013, May 31, 2012
Filed:
Dec 9, 2009
Appl. No.:
13/132920
Inventors:
John W. Mellors - Pittsburgh PA, US
Nicolas Paul Sluis-Cremer - Pittsburgh PA, US
Richard Anthony Whitaker - Loganville GA, US
Brian David Herman - Pittsburgh PA, US
Jong Hyun Cho - Snellville GA, US
Longhu Zhou - Atlanta GA, US
Hongwang Zhang - Tucker GA, US
Nicolas Paul Sluis-Cremer - Pittsburgh PA, US
Richard Anthony Whitaker - Loganville GA, US
Brian David Herman - Pittsburgh PA, US
Jong Hyun Cho - Snellville GA, US
Longhu Zhou - Atlanta GA, US
Hongwang Zhang - Tucker GA, US
International Classification:
A61K 31/7076, A61P 31/18, A61P 31/20, C07H 19/207
US Classification:
514 48, 536 267
Abstract:
The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, and HBV, in human patients or other animal hosts. The compounds are 3′-azido-2′,3′-dideoxy purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 and HBV.